Lymphoma & Plasma Cell Disorders
Conference Coverage
Peripheral blood MRD correlates with treatment benefit in CLL
CHICAGO—Minimal residual disease (MRD) kinetics confirms the high, durable MRD-negativity with venetoclax plus rituximab in relapsed/refractory...
Conference Coverage
DLBCL survival improved with novel antibody-drug conjugate
Big survival gains were reported in patients with relapsed/refractory DLBCL treated with polatuzumab vedotin, bendamustine, and rituximab.
News
‘Excellent’ survival with HCT despite early treatment failure in FL
Autologous and allogeneic hematopoietic stem cell transplantation (HCT) both offer excellent long-term survival in follicular lymphoma (FL)...
Conference Coverage
Interim PET scans identify HL patients with better outcomes
CHICAGO—Interim PET scans can identify a subset of Hodgkin lymphoma (HL) patients with a better outcome suitable for de-escalation treatment after...
From the Journals
British good practice paper offers MCL diagnosis pearls
The good practice paper includes new information on pathology and use of PET/CT scanning in staging of disease.
News
FDA approves pembrolizumab for relapsed/refractory PMBCL
The FDA granted accelerated approval based on results from the KEYNOTE-170 trial.
News
FDA grants pembrolizumab accelerated approval for PMBCL
The US Food and Drug Administration (FDA) granted accelerated approval to the anti-PD-1 therapy pembrolizumab (Keytruda) for the treatment of...
Conference Coverage
Ibrutinib and venetoclax combo promising in frontline CLL
CHICAGO—Ibrutinib combined with venetoclax is showing promising clinical activity in the frontline treatment of patients with chronic lymphocytic...
Conference Coverage
Chemo-free combo provides potential first-line option for FL
CHICAGO—A chemotherapy-free combination of lenalidomide plus rituximab shows similar efficacy and a different safety profile to chemotherapy plus...
News
FDA approves venetoclax for CLL/SLL with or without del 17p
The US Food and Drug Administration (FDA) has approved venetoclax tablets (Venclexta ®) in combination with rituximab to treat patients with...
News
FDA grants regular approval to venetoclax for CLL/SLL
The drug is indicated for patients with CLL or SLL, with or without 17p deletion, who have had at least one prior therapy.